We knocked down HER2 in HR+/HER2-low breast cancer cells and found no difference in the inhibitory effects of the three-agent regimen including CDK 4/6 inhibitor, endocrine therapy combined with neratinib on cell proliferation. This evidence concerns the gene ERBB2 and breast carcinoma.